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Peroxisomal disorders are a group of inherited diseases in man in which either peroxisome biogenesis or one or more peroxisomal functions are
impaired. The peroxisomal disorders identified to date are usually classified in two groups including: (1) the disorders of peroxisome biogenesis,
and (2) the single peroxisomal enzyme deficiencies. This review is focused on the second group of disorders, which currently includes ten
different diseases in which the mutant gene affects a protein involved in one of the following peroxisomal functions: (1) ether phospholipid
(plasmalogen) biosynthesis; (2) fatty acid beta-oxidation; (3) peroxisomal alpha-oxidation; (4) glyoxylate detoxification, and (5) H2O2
metabolism.
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The peroxisomal disorders (PDs) are usually subdivided into
two groups, including: (i) the peroxisome biogenesis disorders
(PBDs); and (ii) the single peroxisomal enzyme (transporter)
deficiencies (PEDs).
The PBD group comprises Zellweger syndrome (ZS),
neonatal adrenoleukodystrophy (NALD); infantile Refsum
disease (IRD) and rhizomelic chondrodysplasia punctata
(RCDP) type 1. After the recognition that mutations in the
same gene can lead to either of the first three disease conditions,
they are nowadays collectively called the Zellweger spectrum
disorders (ZSDs), that constitute a triad of overlapping disorders
with ZS being the most severe, followed by N-ALD and IRD.
Common to all three are liver disease, variable neurodevelop-
mental delay, retinopathy, and perceptive deafness with onset in
the first months of life. In addition, patients with ZS are severely
hypotonic and weak from birth and have distinct facial features,
peri-articular calcifications, severe brain dysfunction associated
with neuronal migration disorders and die before 1 year of age.
Patients with N-ALD have hypotonia, seizures, may have
polymicrogyria, have progressive white matter disease, and
usually die in late infancy. Patients with IRD may have external⁎ Corresponding author.
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doi:10.1016/j.bbamcr.2006.08.010features reminiscent of ZS, but no neuronal migration disorder
and no progressive white matter disease. The cognitive and
motor development varies between severe global handicaps and
moderate learning disabilities with deafness and visual impair-
ment, due to retinopathy.
RCDP type 1 is clinically quite different from the Zellweger
spectrum disorders (ZSDs) although there are some features
shared by RCDP type 1 and the ZSDs including the cranial
facial (broad low nasal bridge, epicanthus, high arched palate,
dysplastic external ears, and micrognathia), and ocular
abnormalities. Indeed, histopathology of the eyes of ZS and
RCDP patients showed a number of important common features
including abnormal corneal epithelium and endothelium, with
mitochondrial proliferation. Furthermore, signs of ganglion
atrophy and photoreceptor degeneration were found, which
occurred earlier in ZS as compared to RCDP. These findings led
Kretzer et al. to suggest a common etiological mechanism
between ZS and RCDP already in 1981 [36]. This suggestion
inspired Heymans et al. [31] to study whether RCDP is a
peroxisomal disorder. RCDP type 1 is not only clinically
different from the ZSDs but also its biochemistry, cell biology,
and genetics are different. Indeed, the ZSDs are now known to
be associated with mutations in a large number of different PEX
genes, including PEX 1,2,3,5,6,10,12,13,14,16,19 and 26 [64]
[85], whereas mutations in PEX7 are associated with RCDP
type 1 [4,47], but not with any of the ZSDs.
Table 1
List of the single peroxisomal enzyme deficiencies
Peroxisomal pathway affected Peroxisomal disease Enzyme defect Gene involved
(1) Ether phospholipid synthesis •Rhizomelic chondrodysplasia punctata Type 2 (DHAPAT deficiency) DHAPAT GNPAT
(2) Peroxisomal beta-oxidation •Rhizomelic chondrodysplasia punctata Type 3 (alkyl-DHAP synthase) ADHAPS AGPS
•X-linked adrenoleukodystrophy ALDP ABCD1
•Acyl-CoA oxidase deficiency ACOX1 ACOX1
•D-bifunctional protein deficiency DBP HSD17B4
• 2-MethylacylCoA racemase deficiency AMACR AMACR
• Sterol carrier protein X deficiency SCPx SCP2
(3) Peroxisomal alpha-oxidation •Refsum disease (phytanoyl-CoA hydroxylase deficiency) PHYH/PAHX PHYH/PAHX
(4) Glyoxylate detoxification •Hyperoxaluria Type 1 AGT AGXT
(5) H2O2-metabolism Acatalasaemia CAT [79] CAT
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single peroxisomal enzyme / transporter deficiencies (PEDs),
which can be subdivided into distinct subgroups on the basis of
the peroxisomal metabolic pathway affected. Table 1 lists the
peroxisomal disorders (PBDs) identified so far and their
classification into distinct subgroups as used throughout this
review. Until recently, mevalonate kinase deficiency was also
believed to be a peroxisomal disorder, but should no longer be
considered a peroxisomal disorder because the earlier claim that
mevalonate kinase is a peroxisomal enzyme has now been
disproven [32].
In this review we will describe the clinical, biochemical, cell
biological, and genetic aspects of each of the PEDs and will
begin by giving a brief update on the function of peroxisomes in
human beings and the enzymes and transporters involved.
2. Metabolic functions of peroxisomes in humans
Peroxisomes play an indispensable role in human physiology
as concluded from the devastating consequences of a defect in
the biogenesis of peroxisomes as observed in Zellweger
patients. The metabolic functions attributed to peroxisomes
are multiple and include both biosynthetic (ether phospholipid
biosynthesis, bile acid synthesis, docosahexaenoic acid synth-
esis) and degradative (fatty acid alpha-oxidation, fatty acid beta-
oxidation, glyoxylate detoxification, et cetera) pathways. Much
of the knowledge on the metabolic functions of peroxisomes
actually comes from studies on body fluids and tissues from
Zellweger patients. The functions of peroxisomes, which are of
key importance to the group of peroxisomal disorders are: (1)
ether phospholipid biosynthesis; (2) fatty acid beta-oxidation;
(3) glyoxylate detoxification, and (4) fatty acid alpha-oxidation.
3. Ether phospholipid biosynthesis and its disorders
3.1. Ether phospholipid biosynthesis
Ether phospholipids are a special class of phospholipids,
which differ from the regular diacyl phospholipids in having an
ether-linkage rather than an ester-linkage at the sn-1 position of
the glycerol backbone. Two groups of ether phospholipids can
be distinguished with either an 1-O-alkyl or an 1-O-alk1-enyl
linkage. The latter phospholipids (1-O-alk1-enyl-2-acyl phos-
phoglycerides) with an alpha-beta unsaturated ether-bond arealso known by their trivial name plasmalogens. Biosynthesis of
ether phospholipids involves the concerted action of enzymes
localized in both peroxisomes and the endoplasmic reticulum.
The ether bond, which is characteristic for ether phospholipids,
is formed by the peroxisomal enzyme alkyl-DHAP synthase
(encoded by AGPS) which turns the acyl-DHAP, generated
from acyl-CoA and dihydroxyacetonephosphate (DHAP) by the
peroxisomal enzyme dihydroxyacetonephosphate acyltransfer-
ase DHAPAT (encoded by GNPAT), into alkyl-DHAP. After
conversion of alkyl-DHAP into alkyl-G3P either in peroxi-
somes or the endoplasmic reticulum, the final steps of ether
phospholipids synthesis are performed by endoplasmic reticu-
lum enzymes (see Brites et al. [5] for review).
3.2. Disorders of ether phospholipid biosynthesis
Two single enzyme deficiencies in the ether phospholipid
biosynthetic pathway have been identified so far. These are: (i)
DHAPAT deficiency, and (ii) alkyl-DHAP synthase deficiency.
3.2.1. DHAPAT deficiency (Rhizomelic chondrodysplasia
punctata type 2)
DHAPAT deficiency was first described in 1992 [82] in a
patient showing all the clinical signs and symptoms of RCDP,
including: (i) cranial facial abnormalities at birth, including a
high forehead, large fontanels, a low/broad nasal bridge,
anteverted nostrils, micrognathia, and a high-arched palate;
(ii) severe hypotonia; (iii) cataract; (iv) dwarfism; (v)
pronounced rhizomelic shortening, especially of the upper
arms, and (vi) striking radiological abnormalities, consistent
with RCDP, although there were no stippled calcifications of
patellae and acetabulum. In order to substantiate the clinical
diagnosis RCDP, erythrocyte plasmalogen levels were deter-
mined and found to be fully deficient. The levels of phytanic
acid in plasma were normal, however. The significance of this
finding was not immediately clear because phytanic acid is
solely derived from exogenous (dietary) sources and may be
completely normal despite a full block in phytanic acid alpha-
oxidation as is the case in RCDP type 1 patients. The same
applies to ZSD patients. Detailed studies in fibroblasts of the
index patient revealed a novel type of RCDP. Indeed, in all
RCDP patients, whose fibroblasts were studied at that time, four
abnormalities were found including: (i) a (partial) deficiency of
DHAPAT; (ii) a marked deficiency of alkyl-DHAP synthase;
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presence of peroxisomal thiolase I (ACAA1/pTH1) in its 44
kDa precursor form with the 41 kDa mature form completely
missing [83]. In fibroblasts from this patient, however, only a
single abnormality was detected, i.e. a full deficiency of
DHAPAT, which was soon found to be caused by mutations in
the gene (GNPAT) coding for DHAPAT. Since this first report a
number of additional patients have been reported. Barr and
colleagues [1] reported the second patient with DHAPAT
deficiency, who also had the severe phenotype. In 1994 Clayton
and co-workers [8] reported on a 21-month-old boy and his 3½-
year-old sister, who both had isolated DHAPAT deficiency.
Both siblings had anteverted nerves, normal limbs, hypotonia,
growth and developmental retardation, and feeding difficulties.
Eczema was present in a younger patient, whereas a cranial CT-
scan showed mild cerebral atrophy. The older sister had
seizures. The same patients plus an additional sibling in the
same family were later reported by Sztriha and co-workers
[70,71]. The third patient in the family had a comparable
clinical presentation, again without rhizomelia. A similar, mild
case of DHAPAT deficiency was reported first by Moser and co-
workers [42] and later described in full detail by Elias et al. in
1998 [15]: the 6½-year-old girl displayed developmental delay,
growth failure and cataract, but no rhizomelia and no cranial
facial dysmorphism.
In all patients with established RCDP type 2 the activity of
DHAPAT is severely deficient, which results in a virtually
complete inability to synthesize ether phospholipids, including
plasmalogens. This is reflected in deficient plasmalogen levels
in all tissues investigated including erythrocytes. Importantly, in
all patients studied thus far, erythrocyte plasmalogen levels are
clearly deficient, which implies that erythrocyte plasmalogen
analysis is a reliable initial biochemical test. Molecular studies
have led to the identification of different mutations in the gene
coding for DHAPAT [50].
3.2.2. AlkylDHAP synthase deficiency (rhizomelic
chondrodysplasia Type 3)
In 1994, the first case of isolated alkyl-DHAP synthase
deficiency (RCDP type 3) was described in a patient showing
all the clinical characteristics of RCDP [80]. Also in this pa-
tient erythrocyte plasmalogen levels were completely deficient
whereas plasma phytanic acid levels were normal. Subsequent
studies in fibroblasts revealed the complete deficiency of alkyl-
DHAP synthase with normal values for DHAPAT and phytanic
acid alpha-oxidation and a normally processed peroxisomal
thiolase. In literature only a single patient has been described
since [10] although three additional patients have been
identified by dr. H.W. Moser, Baltimore, who all showed
classical RCDP with early demise (Dr. H.W. Moser, personal
communication). The patient described by de Vet et al. [10] was
less affected and is still alive at >10 years, showing mild
rhizomelia, generalized contractures, inability to sit or crawl,
cataract, seizures and profound developmental delay. In the
original patient described in Wanders et al. 1994 [80] alkyl-
DHAP synthase was fully deficient, whereas DHAPAT,
phytanic acid alpha oxidation, and peroxisomal thiolase werenormal. Also in the subsequent patient described by de Vet and
colleagues [10] alkyl-DHAP synthase was deficient, but, in
addition, DHAPATactivity was also low with a residual activity
of about 15%. In order to resolve this peculiar finding,
complementation studies were performed, which revealed that
the two patients did belong to the same genetic complementa-
tion group representing alkyl-DHAP synthase deficiency.
Detailed studies by van den Bosch and co-workers [3] have
shown that the deficient activity of DHAPAT in the second case
of alkyl-DHAP synthase deficiency is the secondary conse-
quence of the fact that the alkyl-DHAP synthase protein is
completely absent in this patient due to a homozygous 128-bp
deletion which leads to a premature stop. On the other hand,
studies in fibroblasts from the first patient with alkyl-DHAP
synthase deficiency have shown that the protein is normally
expressed and correctly localized in peroxisomes as established
in fibroblasts from this patient [11]. The protein, however, is
functionally inactive, due to a 1256G>A mutation, causing the
substitution of the amino acid arginine at position 419 by a
histidine [11]. Since DHAPAT is only stable if it forms a
complex with alkyl-DHAP synthase within the peroxisome,
these data explain why DHAPAT activity was found to be fully
normal in fibroblasts from the first patient described by
Wanders et al. [80], but deficient in patient 2 described by de
Vet et al. [10]. Furthermore, these data resolve the puzzling
situation in RCDP type 1 in which DHAPAT has long been
known to be deficient, despite its identification as a typical
PTS1 protein.
In the few alkyl-DHAP synthase-deficient patients studied so
far, erythrocyte plasmalogens levels were deficient like in
RCDP type 1 and type 2 patients. This suggests that erythrocyte
plasmalogen analysis is an excellent method to resolve whether
a particular patient is affected by one of the peroxisomal forms
of RCDP.
4. Peroxisomal fatty acid beta oxidation and its deficiencies
4.1. Peroxisomal fatty acid beta-oxidation
Peroxisomes contain a fatty acid beta-oxidation system
which proceeds via the same principle set of four consecutive
enzymatic reactions as in mitochondria, although the individual
reactions of the beta-oxidation systems are catalyzed by distinct
enzymes. The peroxisomal and mitochondrial beta-oxidation
system serve different functions in human cells and catalyze the
beta-oxidation of different fatty acids and fatty acid derivatives.
Indeed, mitochondria catalyze the beta-oxidation of the bulk of
FAs derived from the diet, including palmitic (C16:0), oleic
(C18:1), linoleic (C18:2) and linolenic (C18:3) acid, whereas
peroxisomes catalyze the beta-oxidation of a different set of
substrates. These include:
(1) Very-long-chain fatty acids (VLCFAs), notably hexacosa-
noic acid (C26:0): VLCFAs are in part derived from
dietary sources but also formed by chain-elongation of
long-chain fatty acids. In humans, most of the C26:0 is
produced by chain elongation.
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acid): pristanic acid cannot be synthesized endogenously
in human beings and is solely derived from exogenous
dietary sources either as pristanic acid itself, or via alpha-
oxidation from its precursor phytanic acid (see Fatty acid
alpha-oxidation).
(3) Di- and trihydroxycholestanoic acid (DHCA and THCA),
which are intermediates in the formation of the primary
bile acids cholic acid and chenodeoxycholic acid from
cholesterol in the liver. After activation, DHCA and
THCA undergo one cycle of beta-oxidation in peroxi-
somes to produce the CoA-esters of chenodeoxycholic
acid and cholic acid, which are subsequently converted
into the corresponding taurine or glycine conjugates
within peroxisomes, followed by export from peroxi-
somes and final excretion into bile.
(4) Tetracosahexaenoic acid (C24:6ω-3). Peroxisomes play
an important role in the formation of docosahexaenoic
acid (C22:6ω-3) [65]. Indeed, recent studies have
established that the formation of C22:6ω-3 from linolenic
acid (C18:3ω-3) proceeds via subsequent steps of chain
elongation and desaturation, but also involves the
peroxisomal fatty acid oxidation system, since tetracosa-
hexaenoic acid is beta-oxidized in peroxisomes to
produce C22:6ω-3 (see [18]).
(5) Long-chain dicarboxylic acids. Recent studies have
shown that at least a long-chain dicarboxylic acid like
hexadecadioic acid, which is the dicarboxylic acid of
palmitic acid, is oxidized exclusively in peroxisomes
[20].
The actual beta-oxidation of all these different FAs in
peroxisomes involves the participation of a number of different
enzymes including two acyl-CoA oxidases, two multifunc-
tional proteins with enoyl-CoA hydratase and 3-hydroxyacyl-
CoA dehydrogenase activities, and two different peroxisomal
thiolases. The two acyl-CoA oxidases, called ACOX1 and
ACOX2 serve different functions with ACOX1 (straight-chain
acyl-CoA oxidase) preferentially reacting with the CoA-esters
of straight-chain FAs, like C26:0, whereas the second acyl-
CoA oxidase, i.e. ACOX2 (branched-chain acyl-CoA oxidase)
catalyses the dehydrogenation of the CoA-esters of 2-methyl
branched-chain FAs, like pristanoyl-CoA and the CoA-esters
of the bile acid intermediates DHCA and THCA [78]. The
enoyl-CoA esters of C26:0, pristanic acid, DHCA and THCA
are all handled by a single bifunctional enzyme catalyzing the
second (hydration) and third (dehydrogenation) steps of
peroxisomal beta-oxidation. This enzyme with both enoyl-
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activ-
ity forms and dehydrogenates D-3-hydroxyacyl-CoA esters
rather than L-3-hydroxyacyl-CoA-esters and is the single
enzyme involved in the oxidation of C26:0, pristanic acid as
well as DHCA and THCA [12–14,33,34,51,53]. Different
names have been given to this enzyme, including D-
bifunctional protein (DBP), D-peroxisomal bifunctional
enzyme (D-PBE), multifunctional enzyme II (MFEII), and
multifunctional protein 2 (MFP2).Peroxisomes also contain a different bifunctional protein,
which forms and dehydrogenates L-3-hydroxyacyl-CoA esters.
Recent evidence suggests that this enzyme is, at least partially,
involved in the peroxisomal oxidation of long-chain dicar-
boxylic acids [20].
Finally, human peroxisomes contain two peroxisomal
thiolases, i.e. pTH1 and pTH2. Human pTH1 is the human
equivalent of the clofibrate-inducible thiolase identified by
Hashimoto and co-workers [41], whereas pTH2 is identical to
the 58 kDa sterol carrier protein x (SCPx) with both thiolase
activity and a sterol carrier protein domain [59]. It is clear now
that pTH2 (SCPx) plays an indispensable role in the oxidation
of 2-methyl branched-chain fatty acids, whereas pTH1 and
pTH2 are both involved in C26:0 oxidation. Fig. 2 depicts the
involvement of the different enzymes in the oxidation of the
different FAs and FA-derivatives.
The enzymes described above are necessary and sufficient
for the beta-oxidation of straight-chain fatty acids like C26:0 as
well as 2-methyl branched-chain fatty acids with the methyl
group in the (2S)-configuration. However, auxiliary enzymes
are needed for the beta-oxidation of (2R)-methyl branched-
chain FAs and unsaturated FAs. Oxidation of (2R)-methyl
branched-chain FAs requires the active participation of an
enzyme, capable of converting (2R)- into (2S)-branched-chain
acyl-CoAs. Studies, notably by Schmitz and Conzelmann and
co-workers [56–58] have shown that peroxisomes contain 2-
methylacyl-CoA racemase (AMACR), which is able to convert
(2R)-methylacyl-CoAs into the corresponding (2S)-methylacyl-
CoAs and vice versa. The importance of this enzyme for
oxidation of 2-methyl branched-chain fatty acids is stressed by
the findings in AMACR-deficient patients in which (2R)-
pristanic acid accumulates as well as (25R) di- and trihydrox-
ycholestanoic acid [17,22,23,60]. The accumulation of the latter
two species is explained by the fact that the 2-methyl group in
DHCA and THCA, which are produced from cholesterol, has
the (25R)-configuration (see Fig. 2).
4.2. The disorders of peroxisomal beta-oxidation
So far 5 different defects in the peroxisomal beta-oxidation
system have been identified, which include: X-linked adreno-
leukodystrophy, acyl-CoA oxidase deficiency, D-bifunctional
protein deficiency, sterol carrier protein X (SCPx) deficiency,
and 2-methylacyl-CoA racemase (AMACR) deficiency. These
diseases will be described below. Biochemical abnormalities,
associated with each of these disorders, are listed in Table 2 (see
also Fig. 2).
4.2.1. X-linked adrenoleukodystrophy
The phenotype of X-linked adrenoleukodystrophy (X-ALD)
varies wildly with at least six phenotypic variants described.
The classification of X-ALD is somewhat arbitrary and based
on the age of onset and the organs principally involved. X-ALD
is the most common single peroxisomal disorder with a
minimum incidence of 1:21.000 males in the USA [2] to
1:15.000 males in France (Aubourg, cited in Kemp et al. (2001))
[35]. The two most frequent phenotypes are childhood cerebral
Table 2
Metabolite abnormalities in each of the single peroxisomal beta-oxidation
deficiencies
Peroxisomal disorder Peroxisomal metabolite
VLCFA Pristanic
acid
Phytanic
acid
DHCA/
THCA
•X-Linked adrenoleukodystrophy ↑ N N N
•Acyl-CoA oxidase deficiency ↑(1) N N N
•D-bifunctional protein deficiency ↑(2) ↑* ↑* ↑(3)
• Sterol carrier protein X (SCPx)
deficiency
N ↑* ↑* ↑
• 2-methylacylCoA racemase
(AMACR) deficiency
N ↑* ↑* ↑
Footnote: (1)=plasma VLCFA-levels may not be elevated in all acylCoA oxidase
deficient patients (see Rosewich et al. [55]; (2)=plasma VLCFA levels may not
always be elevated in all DBP-deficient patients (see Ferdinandusse et al. [19]);
*=plasma pristanic acid and phytanic acid are usually elevated but may be
deceptively low to even normal as a consequence of the reduced dietary intake of
pristanic acid and/or phytanic acid. N=normal.
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CCALD is between 3 and 10 years of age with progressive
behavioral, cognitive and neurologic deterioration, often
leading to total disability within 3 years. The cerebral phenotype
is not only observed in childhood but may also present later in
life in adolescence (adolescence cerebral ALD; ACALD) or
adulthood (adult-cerebral ALD). There is a marked difference
between the cerebral phenotypes on the one hand, and AMN on
the other, since the cerebral phenotype shows an inflammatory
reaction in the cerebral white matter, which resembles, but can
be distinguished from what is observed in multiple sclerosis. In
contrast to CCALD, the inflammatory response is absent or
mild in AMN, which has a much later age of onset (28+9
years), and a much slower rate of progression. Finally, it is
important to mention that approximately 40 to 50% of women,
heterozygous for X-ALD, develop AMN-like symptoms in
middle age or later. Cerebral involvement and adrenocortical
insufficiency are rare, however. For more detailed information
the reader is referred to the paper by Gärtner and Berger
elsewhere in this issue.
4.2.1.1. Biochemistry and molecular basis of X-ALD. The
biochemical hallmark of X-ALD is the accumulation of
VLCFAs in plasma [43], fibroblasts [44], and other cell types
(see [45] for review). Analysis of plasma VLCFAs has proven
to be a powerful diagnostic method with very few, if any, false
negatives. In 15 to 20% of obligate heterozygotes, however, test
results are falsely negative, which makes mutation analysis the
only reliable test for heterozygote identification. Other
peroxisomal metabolites are normal in plasma from X-ALD
patients (see Table 2 and Fig. 2a). The accumulation of VLCFAs
is due to the impaired oxidation of VLCFAs in peroxisomes.
Indeed, the rate of C26:0 oxidation in X-ALD fibroblasts is 20
to 30% of control, compared with a virtually complete
deficiency in fibroblasts from Zellweger patients lacking
peroxisomes.
The X-ALD or ABCD1 gene was identified in 1993, using a
positional cloning strategy [46]. The protein turned out tobelong to the superfamily of ABC transmembrane transporter
proteins and is called ALDP. ALDP is a so-called half ABC-
transporter, which must dimerize to generate the functional
ABC-transporter. Three additional mammalian peroxisomal
half ABC-transporters have been identified, which are closely
related by nucleic acid and protein sequence to ALDP. These are
ALDR, PMP70 and PMP69, encoded by ABCD2, ABCD3, and
ABCD4, respectively. The four transporters may form different
heterodimeric combinations in the peroxisomal membrane.
According to Guimaraes et al. [29] ALDP preferentially forms
homodimeric combinations. Although definitive experimental
evidence is lacking, ALDP has been claimed to catalyze the
transport of VLCFAs, probably in their coenzyme A ester form,
across the peroxisomal membrane. This is inferred from ex-
periments in the yeast S. cerevisiae, which contains two half
ABC-transporters, called Pxa1p and Pxa2p, both showing high
homology with ALDP [61–63] or [30,69]. The Pxa1p/Pxa2p
heterodimer has been shown to transport long-chain acyl-CoA
esters across the peroxisomal membrane. This conclusion has
been disputed by McGuiness et al. [39,40], who showed that the
oxidation of C24:0 is partially deficient in fibroblasts from
patients with a defect in mitochondrial beta-oxidation at the
level of carnitine palmitoyltransferase 1 (CPT1) and very-long-
chain acyl-CoA dehydrogenase (VLCAD). Although the extent
of the deficiency was only limited, these results led McGuiness
et al. [39,40] to conclude that the reduced oxidation of C24:0 in
X-ALD cells is due to mitochondrial abnormalities and that
ALDP somehow facilitates the interaction between peroxi-
somes and mitochondria. Later studies, however, notably by
Oezen et al. [49] showed that mitochondria, at least those
isolated from Abcd1 (−/−) mice, are indistinguishable from
wild type mitochondria in all aspects studied, which includes
normal rates of oxidative phosphorylation and normal P/O
ratios.
Mutation analysis of the ABCD1 gene in X-ALD patients
revealed many different, often private mutations. As of April
2006 the X-ALD mutation database (http://www.X-ALD.nl/)
contains 866 mutations of which 526 (21%) are missense
mutations, 196 (23%) are frame shifts, 84 (10%) are nonsense
mutations, 32 (4%) are amino acid insertions or deletions, and
28 (4%) are large deletions comprising one or more exons. The
majority of X-ALD kindreds have a unique mutation. 435
(50%) non-recurrent mutations have been identified.
4.2.2. Acyl-CoA oxidase deficiency
Acyl-CoA oxidase deficiency was first described by Poll The
et al. in 1988 [51] in two siblings, male and female, from a
consanguineous marriage. Both children showed neonatal onset
hypotonia, delayed motor development, sensory deafness, and
retinopathy, with extinguished electroretinograms. There was
no craniofacial dysmorphia. Although psychomotor develop-
ment was severely delayed both patients showed some progress
in the first 2 years of life after which progressive neurological
regression set in. The cranial CT-scan without contrast
enhancement in the neonatal period was minimally abnormal
in both patients. At 4 years of age a repeated cranial CT-scan
with contrast enhancement was performed in one of the siblings
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and a generally hypodense cerebral white matter. A second
patient was described by Wanders et al. [81]. This patient, when
examined at the age of 3 years and 10 months, showed
generalized hypotonia, failure to thrive, deafness, hepatome-
galy, psychomotor retardation, absent reflexes, and frequent
convulsions. At autopsy, multiple abnormalities were found
including atrophy of skeletal muscles, brain stem ganglions, and
cerebral nerves. Furthermore, in the brain and adrenals large
PAS-positive, sudanophilic astrocytes, and macrophages were
found. The liver was fibrotic. Using complementation analysis
two further patients were identified by Suzuki et al. in 1994
[37,68]. Both patients showed profound hypotonia, dysmorphic
features, including hypertelorism, epicanthus, long nasal bridge,
low-set ears, and polydactyly in the neonatal period and there
was no hepatomegaly or calcific stippling. In the first patients
there were focal seizures of the left arm at 4 months of age.
There was head control at 5 months and crawling at 12 months.
At 32 months of age this patient could walk without assistance.
Since then his motor ability has regressed. At 41 months of age
he could not sit, but he did respond to members of the family by
smiling or crying. The other patient described by Suzuki [68] is
the younger sister of the first patient and clinical manifestations
were quite similar. She could control her head at 6 months of
age, crawled at 18 months and walked with support at 22
months, followed by regression. Both patients were alive at four
and 7 years when reported in 1994. Again, using complementa-
tion analysis, Watkins et al. 1995 [87] identified three additional
patients, followed by a more recent report by Kurian et al. [37],
who described a patient with facial dysmorphia, biphasic
neurodevelopmental delay, sensori-neural hearing loss and
hepatomegaly bringing the total number of patients to nine. In
general, patients with acyl-CoA oxidase deficiency show
moderate neonatal hypotonia, frequent seizures with the onset
typically between 2 and 4 months of age but less severe when
compared with D-bifunctional protein deficiency and usuallyFig. 1. Schematic illustration of the individual transport (ALDP) and enzymatic (A
oxidation of C26:0, pristanic acid and di- and trihydroxycholestanoic acid.controlled with medication. Most patients do not show cranial
facial dysmorphia, although this is not true for all patients.
Many of the patients do show some development, followed by
regression. Renal and skeletal abnormalities and liver disease
are usually not observed in acyl-CoA oxidase deficiency. The
average age of death is much later than in patients with D-
bifunctional protein deficiency.
4.2.2.1. Biochemistry and molecular basis of acyl-CoA oxidase
deficiency. Since acyl-CoA oxidase-1 is only involved in the
beta-oxidation of VLCFAs but not in pristanic acid and di- and
trihydroxycholestanoic acid (Fig. 1), the only abnormality
observed in plasma from patients is elevated VLCFAs (Table 2,
Fig. 2b). Studies in fibroblasts have shown that the oxidation of
C26:0 is markedly deficient with normal pristanic acid beta-
oxidation. Immunofluorescence microscopy analysis of peroxi-
somes usually reveals enlarged peroxisomes, which are reduced
in number. Molecular analysis has so far been performed in only
a few patients [27,55,66].
4.2.3. D-bifunctional protein deficiency
D-bifunctional protein deficiency (DBP deficiency) is one of
the more recently identified peroxisomal disorders and is now
known to be relatively frequent among the group of
peroxisomal beta-oxidation deficiencies, second to X-ALD.
After its first identification by Suzuki et al. [67], and van
Grunsven et al. [73] many patients have been identified. The
availability of methods to diagnose DBP-deficiency has led to
detailed studies in previously published patients, affected by an
isolated defect in the peroxisomal beta-oxidation system of
unknown etiology [6,9,16,38,48,74,77,84]. Furthermore, sev-
eral published patients in whom doubt had arisen about the final
diagnosis could now be reinvestigated. One of these patients
was described by Watkins et al. in 1989 [86]. Interestingly, at
that time it was believed that this patient had a deficiency of the
other peroxisomal bifunctional enzyme, called L-bifunctionalMACR, ACOX1 and 2, DBP, pTH1 and pTH2(SCPx) steps involved in the
Fig. 2. Schematic illustration of the peroxisomal metabolites which accumulate as result of a deficiency of ALDP (a), acyl-CoA oxidase (b), D-bifunctional protein (c),
sterol-carrier protein X (SCPx) (d), and 2-methylacyl-CoA racemase (AMACR) (e).
1713R.J.A. Wanders, H.R. Waterham / Biochimica et Biophysica Acta 1763 (2006) 1707–1720
1714 R.J.A. Wanders, H.R. Waterham / Biochimica et Biophysica Acta 1763 (2006) 1707–1720protein. A second patient who was reinvestigated was described
already earlier by Goldfischer et al. in 1986 [28] as pseudo-
Zellweger syndrome indicating that the clinical signs and
symptoms of this patient were similar to those described for
classical Zellweger syndrome. This patient was originally
believed to have peroxisomal 3-ketoacyl-CoA thiolase defi-
ciency, but upon reinvestigation we found that the true defect in
this patient is again at the level of D-bifunctional protein [24]. A
number of other patients described in literature with an
unknown defect in peroxisomal beta-oxidation, all turned out
to suffer from DBP deficiency as well [19].
D-bifunctional protein is a protein with two catalytic
activities including a 2-enoyl-CoA hydratase unit and a (3R)-
hydroxyacyl-CoA dehydrogenase unit. As a consequence three
different types of DBP deficiency can be distinguished
depending on which activity is deficient: (i) type 1 deficient
patients have a deficiency of both the hydratase and
dehydrogenase activities of DBP (in fibroblasts of virtually all
type 1 deficient patients no DBP protein can be detected by
immunoblotting and upon immunofluorescence using an anti-
body raised against DBP); (ii) type 2 deficient patients, have an
isolated deficiency of the hydratase unit; and (iii) type 3
deficient patients, have an isolated deficiency of the dehydro-
genase unit. This classification can be made on the basis of
enzyme activity measurements in combination with mutation
analysis.
Recently, we reported the clinical, biochemical, and genetic
characteristics of a large cohort of DBP-deficient patients.
Enzyme activity measurements in combination with molecular
data revealed that 27% of the patients were DBP type 1
deficient, 28% type 2 deficient, and 45% type 3 deficient. No
evident differences were found between the clinical signs and
symptoms of patients affected by type 1, 2 or 3 deficiency.
Virtually all patients presented with neonatal hypotonia (98%),
and seizures (93%) within the first months of life. 19 patients
(15%) were reported to have had infantile spasms at any time.
Failure to thrive was observed in 43% of the patients. Visual
system failure, including nistagmus, strabismus or failure to
fixate objects at 2 months was reported in 45% of patients.
Almost none of the patients acquired any psychomotor
development. External dysmorphia was present in 68% of
patients and resembled that of patients with Zellweger
syndrome. Frequently described abnormalities were: high
forehead, high arched palate and large fontanel, long philtrum,
epicanthal folds, hypertelorism, microcephaly, shallow supra-
orbital ridges, retrognatia, and low set ears. Kaplan–Meier
survival analysis revealed that all type 1 deficient patients died
within the first 14 months of life (mean age of death: 6.9
months), whereas the mean age of death for type 2 and type 3
deficiency was 10.7 months and 17.6 months. The major cause
of death was pneumonia for almost all patients. Only five of the
patients showed prolonged survival (>5 years), one of whom
was a type 2 patient and the other 4 type 3 patients.
4.2.3.1. Biochemistry and molecular basis of
DBP-deficiency. D-bifunctional protein holds a central posi-
tion in the peroxisomal fatty acid beta-oxidation pathway and isinvolved in the beta-oxidation of C26:0, pristanic acid, as well
as di- and trihydroxycholestanoic acid. This implies that, in
principle, patients with DBP-deficiency would show the
accumulation of C26:0, pristanic acid, and di- and trihydrox-
ycholestanoic acid in plasma (Fig. 2c). It is now clear, however,
that this full set of peroxisomal metabolite abnormalities is not
seen in all DBP-deficient patients. Indeed, in 50 of the 53
patients in whom plasma C26:0 levels and the C26:0/C22:0
ratio could be analyzed, definite abnormalities were found. In
the remaining three patients a normal profile of VLCFAs was
found whereas phytanic acid and pristanic acid levels were also
normal as well as the bile acid intermediates THCA and DHCA.
In contrast, a clearly abnormal VLCFA profile was observed in
fibroblasts from these three patients, which points to a
discrepancy between results in plasma as compared to
fibroblasts. In the 50 patients with abnormal plasma VLCFAs,
phytanic and pristanic acid levels varied considerably, which
follows logically from the fact that both compounds originate
from dietary sources only. As first reported by van Grunsven
et al. [72] DPB-deficient patients may show no accumulation
of THCA and DHCA. In the large cohort study by
Ferdinandusse et al. [19] 12 patients (26%) had no accumula-
tion of THCA and DHCA. Docosahexaenoic acid (DHA) and
arachidonic acid (AA) were determined in only a small
number of patients. In 43% reduced levels of DHA and AA
were found in plasma whereas in erythrocytes only a single
patient had a marginally decreased DHA level. Plasmalogens
in erythrocytes were normal in all DBP-deficient patients
studied. Interestingly, biochemical analysis showed that there
is a good correlation between several biochemical parameters
and the survival of DBP-deficient patients with C26:0 beta-
oxidation in cultured skin fibroblast being the best predictive
marker in terms of life expectancy. The fact that three patients
were identified without any biochemical abnormalities in
plasma indicates that D-bifunctional protein deficiency cannot
be excluded on the basis of measurement of peroxisomal
parameters in plasma only. Molecular analysis of the
HSD17B4 gene has revealed a large number of often private
mutations with only one mutation being more frequent [25,73].
4.2.4. Sterol carrier protein X (SCPx) deficiency
Sterol carrier protein X (SCPx) deficiency has so far been
described in a single patient who was only studied in detail at 44
years of age, following a 20-year history of dystonic head
tremor and spasmodic torticollis. At 29 years of age,
hypergonadotrophic hypogonadism and azoospermia were
diagnosed. Cranial MRI revealed a number of abnormalities
including bilateral hyper intense signals in the thalamus,
butterfly-like lesions in the ponds, as well as lesions in the
occipital region without gadolinium enhancement. Neurological
examination revealed hyposmia, pathological saccadic eye
movements, and a slight hypoacusis. Ophthalmological inves-
tigations revealed no abnormalities. Nerve conduction studies
of the lower extremities showed a predominantly motor and
slight sensory neuropathy with conduction blocks in the tibial
nerves, reduced motor action potentials in the left peroneal
nerve, and reduced amplitude of the left sural nerve.
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and the grey and white matter abnormalities observed upon
MRI, raised the possibility of AMACR deficiency despite the
absence of retinitis pigmentosa, which is a frequent finding both
in AMACR deficiency as well as in Refsum disease. Detailed
laboratory investigations revealed slightly abnormal di- and
trihydroxycholestanoic acid levels, whereas pristanic acid was
clearly elevated (>10-fold the upper limit of normal). Plasma
VLCFAs were completely normal. Taken together, these
abnormalities clearly pointed to a defect in the peroxisomal
metabolism of 2-methyl branched-chain fatty acids.
4.2.4.1. Biochemistry and molecular basis of SCPx
deficiency. Studies in fibroblasts from the index patient
revealed normal oxidation of C26:0 whereas the beta-oxidation
of pristanic acid was markedly deficient with residual activity
amounting to <10% of mean control. These results pointed to
either branched-chain acyl-CoA oxidase, 2-methylacyl-CoA
racemase, or sterol carrier protein X (SCPx) as deficient enzyme
(see Fig. 1). Subsequent enzyme activity measurement showed
normal activities of branched acyl-CoA oxidase as well as 2-
methyl acyl-CoA racemase. In contrast, the activity of SCPx
was fully deficient. Immunoblot analysis showed the absence of
both the full-length 58-kDa SCPx as well as the 46-kDa thiolase
domain of SCPx in fibroblasts of the patient. In contrast, the 13-
kDa SCP2 protein was normally present. Molecular analysis
revealed a homozygous 1-nucleotide insertion, 545_546insA
leading to a frame shift and premature stop codon (I184fsX7)
[21].
As shown in Fig. 2d pristanic acid and the bile acid
intermediates di- and trihydroxycholestanoic acid are the
expected peroxisomal metabolites to accumulate in SCPx
deficiency.
4.2.5. 2-Methyl-acylCoA racemase (AMACR) deficiency
AMACR deficiency was first described in 2000 by
Ferdinanusse et al. [17] in three patients, two of whom suffered
from adult-onset sensorymotor neuropathy. One patient also had
pigmentary retinopathy, reminiscent of Refsum disease, as well
as epilepsy, migraine and depression, whereas the second patient
had pyramidal signs. The third patient was a child without
neuropathy but it should be noted that this child also had
Niemann–Pick type C. Interestingly, Setchell et al. [60] reported
two siblings with racemase deficiency but a completely different
phenotype. Both patients displayed fulminant liver disease,
starting at early age. The index patient presented at 2 weeks of
age with coagulopathy, vitamin D and E deficiency and mild
cholestasis. Plasma analysis revealed elevated levels of the bile-
acid intermediates di- and trihydroxycholestanoic acid (DHCA
and THCA). Furthermore, plasma VLCFAs, phytanic acid, and
red blood cell plasmalogens were all normal, whereas pristanic
acid was markedly elevated (10-fold). These data suggested
AMACR deficiency, which was confirmed in fibroblasts [75].
Remarkably, a previous child in the family had died earlier at 5.5
months of age from an intracranial bleed secondary to vitamin K
deficiency and his liver was harvested for orthotopic transplan-
tation (OLT) and placed into a 28-month-old child with end-stage liver disease. Studies in the recipient revealed marked
elevation of both (25R)-THCA and (25R)-DHCA in urine
indicating that the sibling, whose liver was transplanted, had also
been affected by AMACR deficiency. This finding prompted
institution of a therapy involving ursodeoxycholic acid. The
recipient has remained in good health 8 years after transplanta-
tion while still receiving ursodeoxycholic acid, at least when
reported in 2003 [60]. Interestingly, the patients described by
Setchell et al. [60] were homozygous for the same mutation as
described by Ferdinandusse et al. [17] in the two patients with
adult-onset sensory motor neuropathy. The mutation which
changes a serine at position 52 by a proline leads to a complete
loss of enzyme activity as established by expression studies in E.
coli [17]. Clarke et al. [7] have described an additional patient
with tremor, retinitis pigmentosa, and deep white matter MRI
changes, who subsequently developed encephalopathy with left
hemiparesis and an unchanged MRI. Taken together, these data
suggest that AMACR deficiency can have two wildly different
phenotypic presentations, one characterized by early onset liver
failure, which may resolve, but may also lead to early death, as
described by Setchell et al. [60], whereas the other presentation
is dominated by a late onset sensory neuropathy plus additional
features.
4.2.5.1. Biochemistry and molecular basis of racemase
deficiency. AMACR plays a crucial role in the degradation of
FAs with a methyl group in the (2R)-configuration such as (2R)-
pristanic acid, (25R)-THCA, and (25R)-DHCA (Fig. 1). In all
patients with AMACR deficiency reported so far, pristanic acid,
THCA and DHCA have been found to accumulate, which
follows logically from the role of AMACR in the oxidation of
pristanic acid as well as di- and trihydroxycholestanoic acid, but
not C26:0 (see Fig. 2e). It has been established that racemase-
deficient patients accumulate exclusively the (25R)-isomer of
free and taurine-conjugated DHCA and THCA, whereas in
patients with cholestatic liver disease for instance, both (25R)-
and (25S)-isomers accumulate [22,60].
Interestingly, AMACR is a protein equipped with both a
mitochondrial and peroxisomal targeting signal, which explains
its presence in both mitochondria and peroxisomes. Mitochon-
drial AMACR plays a similar crucial role in the degradation of
(2R)-FAs just like peroxisomal AMACR. One of the (2R)-FAs,
the oxidation of which is dependent on mitochondrial AMACR
activity, is (2R, 6R)-dimethylheptanoic acid, which is produced
from pristanic acid by beta-oxidation. Pristanic acid is a mixture
of two diastereomers including (2R, 6R, 10R) and (2S, 6R, 10R)
pristanic acid. Oxidation of the (2R-) but not the (2S)-form is
deficient in case of AMACR deficiency. Hence, one would
expect accumulation of (2R, 6R)-dimethylheptanoic acid in
patients with racemase deficiency. However, no specific fatty
acid abnormalities resulting for the deficiency of mitochondrial
AMACR in AMACR deficient patients have been documented
in literature.
Mutation analysis has been performed in all patients reported
so far. Remarkably, four of the patients were homozygous for a
point mutation (154T>C), which leads to a single amino acid
substitution (S52P).
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5.1. Fatty acid alpha-oxidation
Fatty acids with a methyl group at the 3-position cannot be
beta-oxidized because the 3-methyl group simply blocks beta-
oxidation. Fortunately, there are other mechanisms by which
such FAs can be degraded including alpha- and omega-
oxidation. Alpha-oxidation involves the oxidative decarbox-
ylation of 3-methyl FAs to produce 2-methyl FAs, which can be
degraded by beta-oxidation. In higher eukaryotes, including
humans, peroxisomes are the sole site of alpha-oxidation. The
enzymatic machinery required for FA alpha-oxidation, has been
resolved in recent years and requires the concerted action of 3
enzymes including: (1) phytanoyl-CoA hydroxylase; (2) 2-
hydroxyphytanoyl-CoA lyase, and (3) pristanal-dehydrogenase
as described in detail elsewhere in this volume. The actual
decarboxylation is catalyzed by the enzyme 2-hydroxy
phytanoyl-CoA lyase, which splits 2-hydroxyphytanoyl-CoA,
the product of the first enzyme of the pathway, i.e. phytanoyl-
CoA hydroxylase, into formyl-CoA and pristanal. Subse-
quently, pristanal is oxidized into pristanic acid via a
peroxisomal aldehyde dehydrogenase, which has not been
identified yet. Pristanic acid, which now has its first methyl-
group at the 2-position, can then be degraded by beta-
oxidation. The first two enzymes, including phytanoyl-CoA
hydroxylase and 2-hydroxyphytanoyl-CoA lyase have been
identified in different species. Human phytanoyl-CoA hydro-
xylase is a typical PTS2 protein which explains why it is not
only deficient in Refsum disease but also in rhizomelic
chondrodysplasia punctata type 1 (RCDP type 1), which is
caused by mutations in the PEX7 gene encoding the PTS2
receptor. Human 2-hydroxyphytanoyl-CoA lyase is a typical
PTS1 protein [26].
5.2. The disorders of fatty acid alpha-oxidation
5.2.1. Refsum disease
Refsum disease usually presents in late childhood with
progressive deterioration of night vision, the occurrence of a
progressive retinitis pigmentosa, and anosmia, later in life
followed by deafness, ataxia, polyneuropathy, ichthyosis and
cardiac arrhythmias. Short metacarpals and metatarsals are also
found in some 30% of Refsum disease patients. Furthermore,
psychiatric disturbances have been reported in a subset of
patients. It is quite clear now that only few patients develop the
full spectrum of clinical signs and symptoms originally defined
by Refsum [54]. Indeed, a study of 16 Refsum disease patients
with full clinical information for a period for up to 60 years
revealed that all 16 patients developed retinitis pigmentosa, 15
out of 16 developed anosmia, whereas neuropathy, deafness and
ataxia was only found in 11, 10 and 8 patients, respectively [88].
Finally, ichthyosis was only present in 4 of the 16 patients
studied. Refsum disease is one of the few peroxisomal disorders
for which a therapy has been developed which is based on the
dietary restriction of phytanic acid. The average human daily
diet intake of phytanic acid in western countries amounts to 50to 100 mg. Restriction of common phytanic acid containing
foods, such as butter, cheeses, lamb, beef and certain fish, helps
to lower plasma phytanic acid levels, which may stop the
progression of the peripheral neuropathy with improved muscle
strength and regression of ichthyosis and correction of non-
specific abnormalities of electrocardiogram.
5.2.2. Biochemistry and molecular basis of Refsum disease
Plasma phytanic acid is generally considered to be an
excellent marker for Refsum disease since all Refsum disease
patients have so far been found to have markedly elevated
plasma phytanic acid levels, even if they are on therapy.
Although this may be true for patients with classical Refsum
disease caused by mutations in the phytanoyl-CoA hydroxylase
gene, the situation may be different in those patients in which
PEX7 is mutated. Indeed, in these patients plasma phytanic
acid levels are generally much lower, and recent studies by Horn
et al. (manuscript submitted for publication) have shown that
levels can actually be completely normal. If plasma phytanic
acid levels are elevated additional studies, preferably in
fibroblasts, should be done to pinpoint the underlying defect.
In all Refsum disease patients studied to date whether mutated
in PAHX or PEX7, discrimination between the two forms of
Refsum disease can be made by performing detailed studies in
fibroblasts, especially by analyzing other PTS2 proteins, like
peroxisomal thiolase and alkyl-DHAP synthase, using immu-
noblot analysis, enzyme activity measurements, and immuno-
fluorescence microscopy analysis, followed by molecular
analysis of the two different genes [79].
6. Glyoxylate detoxification and its disorders
6.1. Glyoxylate detoxification
In humans, peroxisomes play a crucial role in the
detoxification of glyoxylate as exemplified by the devastating
consequences of a deficiency of the peroxisomal enzyme
alanine glyoxylate aminotransferase (AGT) in hyperoxaluria
type 1. AGT catalyses the transamination of glyoxylate to
glycine with alanine as the preferred amino group donor. It is
not exactly known from which precursors glyoxylate is formed.
If glyoxylate is not immediately detoxified by AGT, either due
to its deficient activity in peroxisomes or its mislocalization to
mitochondria as described below, glyoxylate will accumulate in
peroxisomes and will either be reduced to glycolate or oxidized
to oxalate. Glycolate is water soluble and can be excreted via the
urine. This is not true, however, for oxalate, which precipitates
as calcium oxalate. Deposition of calcium oxalate within the
kidney parenchymatous tissue (nephrocalcinosis) or the renal
pelvis/urinary tract (urolithiasis) continues until eventually
renal function is impaired causing subsequent sequelae, like
uremia and systemic oxalosis. The failure to clear oxalate from
the body leads to its further deposition in almost all areas of the
body, affecting multiple tissues in addition to the kidneys and
urinary tract, including: (a) the myocardium with heart block,
myocarditis, and cardioembolic stroke; (b) the nerves (periph-
eral neuropathy); (c) bone (bone pain, multiple fractures,
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marrow, and (f) other organs.
6.1.1. Primary hyperoxaluria type 1
Primary hyperoxaluria type 1 (PH1) is clinically variable
both in symptoms and timing. In most patients, first symptoms
start before 5 years of age. There is an enormous spread,
however, in the ages at which the disease becomes apparent,
which can be as early as the first year of life or even beyond the
5th decade. In its severe neonatal presentation PH1 is
characterized by rapidly progressive oxalosis, renal failure
and early death.
The most common method of diagnosing PH1 is by
measuring urinary oxalate excretion. Markedly elevated urinary
oxalate levels are usually indicative for either PH1 or a second
type of hyperoxaluria, PH2, which is due to a deficiency of
glyoxylate reductase. For differential diagnosis, urinary glyco-
late and L-glycerate must be measured. It should be noted that a
significant number of PH1 patients (up to 25%) with proven
AGT deficiency have hyperoxaluria but no hyperglycolic
aciduria. At the other extreme, some PH1 patients have extreme
hyperglycolic aciduria with only mildly elevated oxalate
excretion. In addition, isolated hyperglycolic aciduria and
concomitant hyperoxaluria and hyperglycolic aciduria have
been found in patients with normal AGT levels.
Definitive diagnosis of PH1 and PH2 requires enzymatic
studies and subsequent molecular analysis. Enzymatic diag-
nosis of PH2 is straightforward, since the enzyme glyoxylate
reductase can be measured reliably in lymphocytes. Enzymatic
diagnosis of PH1 is much less straightforward for two reasons.
Firstly, in contrast to glyoxylate reductase, AGT is only
expressed in liver, which requires a percutaneous liver needle
biopsy. Secondly, and more importantly, although AGT can be
measured reliably in minimal amounts of liver material, the
results of AGT enzyme testing are not unequivocal. The reason
is that AGT activity may be quite normal as measured in a
human liver homogenate, but may be inactive under in vivo
conditions because of its mislocalization to the mitochondrion.
This astonishing phenotype of an enzyme being functionally
inactive because of its localization in the wrong compartment
obviously complicates the results of the AGT enzyme assay.
Since this peroxisome-to-mitochondrion-mistargeting pheno-
type is quite frequent, there is a strong case for direct molecular
analysis of the AGXT gene as we do in our own centre, since the
underlying cause for the mistargeting of AGT to the
mitochondrion has been established now. Indeed, a Gly170Arg
substitution on the background of the minor AGXT allele
(frequency in the normal population : 4%) leads to mistargeting
of 90% of AGT to the mitochondrion. The same is true for the
Phe152Ile mutation. In addition to these two mutations more
than 50 additional mutations in the AGXT gene have been
identified which, in general, render the enzyme inactive without
changing its subcellular localization.
6.1.2. Treatment
PH1 is one of the few peroxisomal diseases for which some
therapeutic options are available. Treatment of PH1 is directedtowards: (a) decreasing the production of oxalate by inhibiting
oxalate synthesis, and (b) increasing the solubility of oxalate at a
given urinary concentration of oxalate. Most of the efforts have
concentrated on ways to increase the solubility of calcium
oxalate with high fluid intake and alkalinization of the urine as
the main stays. Indeed, excessive volume is necessary to help
excrete the enormous amounts of endogenously reproduced
oxalate. Haemodialysis can remove large quantities of oxalate
and its precursors. Importantly, a substantial percentage of PH1
patients respond to pyridoxin. Indeed, pyridoxin at the usual
daily dose of 1000 mg/m2 body surface area can bring about a
substantial reduction in the production and excretion of oxalate,
except in patients with a pyridoxin-resistant form of the disease.
The efficacy of pyridoxin is probably directly related to the
extent to which AGT is deficient. Indeed, if there is some
residual activity, high levels of pyridoxal phosphate, which is the
obligatory cofactor in the AGT enzyme reaction, may allow
residual enzyme activity operate optimally. In this way, flux
through AGT may be stimulated substantially, leading to a
reduced production of oxalate. Recent studies have shown a
clear association between homozygosity for the two mistarget-
ing mutations Gly170Arg and Phe152Ile, and pyridoxin
responsiveness, the reason being that pyridoxin is able to
interfere with the mistargeting of AGT to the mitochondria
thereby increasing the residual activity in peroxisomes from 5 to
10%. In our experience, all patients homozygous for the
Gly170Arg substitution with a preserved renal function at the
time of diagnosis, were able to preserve renal function
throughout the follow-up period when treated with pyridoxin,
high fluid intake, and potassium citrate [76]. In case of pyridoxin
insensitivity combined liver / kidney transplantation is
warranted.
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